●Uninhibited antibiotic target discovery via chemical genetics. Poole, K. Nature Biotechnology December (2004)

A News and Views article about a new way to identify the bacterial targets and resistance mechanisms of novel antimicrobials.

●A series of articles on anti-infectives.Nature Reviews Microbiology December (2004)

Articles include:

●Epidemiological interpretation of antibiotic resistance studies — what are we missing? Schwaber, M. J., De-Medina, T. & Carmeli, Y.

●Antibiotic resistance: a view from the prescriber. Finch, R. G.

●The life and times of ivermectin — a success story. Ömura, S. & Crump, A.

●Antisense, siRNA, and the role of Toll-like receptors. Agrawal, S. & Kandimalla, E. R. Nature Biotechnology December (2004)

●Putting the opium in poppy to sleep. Memelink, J. Nature Biotechnology December (2004)

●Transporter of a malaria catastrophe. Wellems, T. E. Nature Medicine November (2004)

Knowledge of the mechanisms of amantadine, normally used to treat influenza, could lead to the development of new treatments for malaria.

●Treating cancer's kinase 'addiction'. Baselga, J. & Arribas, J. Nature Medicine November (2004)

●Recombinant protein therapeutics: success rates, market trends and values to 2010. Pavlou, A. K. & Reichert, J. Nature Biotechnology December (2004)

●The articles listed below are published in Nature Reviews Cancer (December 2004) to form a joint Focus on Kinases in cancer that includes articles in this issue of Nature Reviews Drug Discovery.

●Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Besson, A., Assoian, R. K. & Roberts, J. M.

●Targeting the mitogen-activated protein kinase cascade to treat cancer. Sebolt-Leopold, J. S. & Herrera, R.

●Aurora-kinase inhibitors as anticancer agents. Keen, N. & Taylor, S.

●Gefitinib — a novel targeted approach to treating cancer. Herbst, R. S., Fukuoka, M. & Baselga, J.